Roche Holding AG ADR Stock
€39.32
Your prediction
Roche Holding AG ADR Stock
Pros and Cons of Roche Holding AG ADR in the next few years
Pros
Cons
Performance of Roche Holding AG ADR vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Roche Holding AG ADR | -0.860% | 2.057% | 9.848% | 10.110% | 18.130% | -6.232% | 5.524% |
| Novartis AG ADR | -1.320% | -0.885% | 3.226% | 6.161% | 18.644% | 43.590% | 49.333% |
| Bayer AG ADR | -0.740% | -6.294% | -0.741% | 2.290% | 35.081% | -42.735% | -41.739% |
| Novo Nordisk A/S ADR | -2.850% | -3.254% | 5.597% | -54.583% | -41.328% | -54.372% | -19.590% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Roche Holding AG (RHHBY), a multinational healthcare company based in Switzerland, stands strong with its broad and diversified portfolio. A closer look into Roche's financial statements prominently reveals a robust business model underpinned by substantial revenues and a profitable margin.
Observing Roche's income statements over the past three years, the figures showcase an impressive gross profit with a steady upward trend. This consistency strongly indicates a robust operating model and proficient managerial efficiency. With increasing net income, the company seems to have experienced notable business and financial growth, reinforcing the credibility of the investment.
Roche also earns recognition for its significant investment in research and development, crucial for pharmaceutical companies. The data reveals a substantial annual expenditure, reflecting Roche's commitment to future growth and revolutionizing pharmaceutical breakthroughs, leading to a sustainable competitive advantage.
Comments
News
Watch Out Eli Lilly, This Pharma Giant Is Gunning to Be a Top Player in the Obesity Market
Eli Lilly (NYSE: LLY) is the most valuable healthcare stock in the world, with a market capitalization of more than $760 billion. It has been soaring in recent years due to the success of its highly
Analog Devices (ADI) Q3 2025 Earnings Transcript
Image source: The Motley Fool.
Wednesday, August 20, 2025 at 10 a.m. ET
Chairman, President, and Chief Executive Officer — Vincent Roche
Source Fool.com
Why Weight-Loss Developer Stocks Tumbled on Tuesday
Makers of weight-loss drugs, the hottest segment of the pharmaceutical market just now, weren't looking so hot on the stock exchange Tuesday. A pronouncement from President Trump about the category